XML 41 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Source
The following table represents disaggregation of royalties, Captisol, service revenue and contract revenue (in thousands):

Three months ended
March 31,
20202019
Royalties
Kyprolis$4,405  $3,833  
Evomela1,576  911  
Other584  601  
Promacta—  14,193  
$6,565  $19,538  
Captisol$21,109  $8,959  
Service Revenue$3,357  $3,883  
Contract Revenue
License Fees$975  $850  
Milestone334  10,254  
Other821  —  
$2,130  $11,104  
Total$33,161  $43,484  
Schedule of Short-Term Investments
Our investments consist of the following at March 31, 2020 and December 31, 2019 (in thousands):
March 31, 2020December 31, 2019
Amortized costGross unrealized gainsGross unrealized lossesEstimated fair valueAmortized costGross unrealized gainsGross unrealized lossesEstimated fair value
Short-term investments
     Bank deposits$284,855  $157  $(1,398) $283,614  $411,690  $188  $(3) $411,875  
     Corporate bonds62,191  21  (1,666) 60,546  63,818  161  —  63,979  
     Commercial paper127,928   (273) 127,660  210,525  43  (16) 210,552  
     Corporate equity securities4,506  430  (3,483) 1,453  4,506  416  (1,850) 3,072  
     Mutual fund150,747  —  (2,794) 147,953  250,635  —  (249) 250,386  
     Warrants—  58  —  58  —  125  —  125  
$630,227  $671  $(9,614) $621,284  $941,174  $933  $(2,118) $939,989  
Schedule of Available-for-Sale Debt Securities
The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):

March 31, 2020
Amortized CostFair Value
Within one year$401,338  $400,627  
After one year through five years73,636  71,193  
After five years—  —  
Total$474,974  $471,820  

The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):

Less than 12 months12 months or greaterTotal
Gross
Unrealized
Losses
Estimated
Fair Value
Gross
Unrealized
Losses
Estimated
Fair Value
Gross
Unrealized
Losses
Estimated
Fair Value
March 31, 2020
Bank deposits$(1,398) $214,597  $—  $—  $(1,398) $214,597  
Corporate bonds(1,666) 40,460  —  —  (1,666) 40,460  
Commercial paper(273) 110,666  —  —  (273) 110,666  
Total$(3,337) $365,723  $—  $—  $(3,337) $365,723  
December 31, 2019
Bank deposits$(3) $58,584  $—  $—  $(3) $58,584  
Commercial paper(16) 79,363  —  —  (16) 79,363  
Total$(19) $137,947  $—  $—  $(19) $137,947  
Schedule of Goodwill and Other Identifiable Intangible Assets
Goodwill and other identifiable intangible assets consist of the following (in thousands):
March 31,December 31,
20202019
     Goodwill$94,341  $95,229  
Definite lived intangible assets
     Complete technology242,813  242,813  
          Less: accumulated amortization(1)
(53,728) (50,203) 
     Trade name2,642  2,642  
          Less: accumulated amortization(1,213) (1,180) 
     Customer relationships29,600  29,600  
          Less: accumulated amortization(13,594) (13,224) 
Total goodwill and other identifiable intangible assets, net$300,861  $305,677  
(1) accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.
Schedule of Commercial License Rights
Commercial license and other economic rights consist of the following (in thousands):

March 31,December 31,
20202019
Aziyo and CorMatrix$17,696  $17,696  
Palvella10,000  10,000  
Selexis8,602  8,602  
Dianomi2,000  2,000  
38,298  38,298  
Less: accumulated amortization attributed to principal or research and development(21,939) (18,208) 
Less: credit loss adjustments(5,978) —  
   Total commercial license and other economic rights, net$10,381  $20,090  
Schedule of Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
March 31,December 31,
20202019
Compensation$2,321  $1,986  
Professional fees690  1,135  
Amounts owed to former licensees383  381  
Royalties owed to third parties1,062  —  
Return reserve2,899  3,027  
Current operating lease liabilities1,483  1,242  
Accrued interest1,437  690  
Other1,573  1,375  
     Total accrued liabilities
$11,848  $9,836  
Schedule of Accounting for Share-Based Compensation The following table summarizes share-based compensation expense recorded as components of research and development expenses and general and administrative expenses for the periods indicated (in thousands):
Three months ended
March 31,
20202019
Share-based compensation expense as a component of:
Research and development expenses$2,397  $2,127  
General and administrative expenses3,256  3,220  
$5,653  $5,347  
Schedule of Fair-Value Options Awarded to Employees and Directors
The fair-value for options that were awarded to employees and directors was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions:
Three months ended
March 31,
20202019
Risk-free interest rate1.4%2.5%
Dividend yield
Expected volatility47%44%
Expected term4.75.1
Schedule of Computation of Basic and Diluted Earnings per Share
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
Three months ended
March 31,
20202019
Weighted average shares outstanding:16,529  20,447  
Dilutive potential common shares:
     Restricted stock—  45  
     Stock options—  785  
Shares used to compute diluted income per share16,529  21,277  
Potentially dilutive shares excluded from calculation due to anti-dilutive effect10,144  7,015